NEWS AND EVENTS
that time again and the Urology team is striving to have an impact
on the face of men’s health. Movember is an annual movement where men grow a mustache to raise
awareness about men’s health - prostate cancer, testicular cancer and
mental health issues such as depression.
encourage everyone to join our team, #UICGotMustache, on the
UIC Movember 3V3 Basketball Tournament and Men’s Health Fair
Saturday, November 20
11:00am – 3:00pm
UIC East Campus Student Recreation Facility
Registration $20 per team and each team can have 4 players.
Click HERE to register.
Testing for Prostate Cancer - Questions and Answers
Prostate Cancer is the most common type of cancer for men, except skin cancer. Smart PSA testing raises the chance of finding a dangerous cancer and treating before it spreads. Read our brochure and speak to your primary care provider to request a test.
Cancer Researcher Is Collaborator on Large DoD Award
Michael Abern, M.D.,
assistant professor and director of urologic oncology and a
widely respected expert on prostate cancer, is a collaborator on
a nearly $600,000 prostate cancer research grant awarded by the
U.S. Department of Defense (DoD), the Department of Urology
Dr. Abern, whose ongoing work with
DoD will contribute to the three-year project, will collaborate
with Larisa Nonn, Ph.D. associate professor of pathology, said
Craig Niederberger, M.D., professor and head of the Department
and professor of bioengineering.
The grant is
part of the Congressionally Directed Medical Research Programs of
the U.S. Army’s Medical Research and Materiel. The
clinical test Drs. Nonn and Abern will conduct relates to the
role of serum microRNAs, also known as miRs, that are associated
with low-risk prostate cancer. Their research investigates
the biological significance of miRs and whether they originate in
the prostate or elsewhere.
is critical toward understanding the biology of prostate
cancer,” said Dr. Abern. “Confirmation of miRs’
role could help lead to improved risk stratification - and
ultimately treatment decisions - that go beyond the
prostate-specific antigen (PSA) method, the current resource
typically employed. A test that will predict the behavior
of prostate cancer would be a critical step in determining what
the best treatment strategy will be for our patients.”
09/19/2015: Gail S. Prins, Ph.D. received
the ‘Innovator of Today Alumni Award’ from the
College of Medicine during the College of Medicine Gala on
September 19, 2015. Click
to find out more details.
Urology is now on facebook and twitter